Yen, C. Et Al. 2017. KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). ESMO Asia Congress , (Singapore, Singapore).

Yen, C., Machiels, J., Licitra, L., Rischin, D., Waldron, J., Burtness, B., ... Gregoire, V.(2017). KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) . ESMO Asia Congress, Singapore, Singapore

Yen, C-J. Et Al. "KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)," ESMO Asia Congress, Singapore, Singapore, 2017

Yen, C-J. Et Al. "KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)." ESMO Asia Congress , Singapore, Singapore, 2017

Yen, C. Et Al. (2017) . "KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)." ESMO Asia Congress , Singapore, Singapore.

@conferencepaper{conferencepaper, author={C-J. Yen Et Al. }, title={KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)}, congress name={ESMO Asia Congress}, city={Singapore}, country={Singapore}, year={2017}}